alzheimer



alzheimers

alzheimers

Alzheimer's disease
Classifications and external resources
ICD-10 G30
ICD-9 331.0
OMIM 104300
DiseasesDB 490
MedlinePlus 000760
eMedicine neuro/13 
Dementia in Alzheimer's disease
Classifications and external resources
ICD-10 F00
ICD-9 290.1

"Alzheimer" redirects here. For other uses, see Alzheimer (disambiguation).

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive deterioration together with declining activities of daily living and neuropsychiatric symptoms or behavioral changes. It is the most common cause of dementia.

The most striking early symptom is loss of short term memory (amnesia), which usually manifests as minor forgetfulness that becomes steadily more pronounced with illness progression, with relative preservation of older memories. As the disorder progresses, cognitive (intellectual) impairment extends to the domains of language (aphasia), skilled movements (apraxia), recognition (agnosia), and those functions (such as decision-making and planning) closely related to the frontal and temporal lobes of the brain as they become disconnected from the limbic system, reflecting extension of the underlying pathological process.

This pathological process consists principally of neuronal loss or atrophy, principally in the temporoparietal cortex, but also in the frontal cortex, together with an inflammatory response to the deposition of amyloid plaques and neurofibrillary tangles.

The ultimate cause of the disease is unknown. Genetic factors are known to be important, and autosomal dominant mutations in three different genes (presenilin 1, presenilin 2, and amyloid precursor protein) have been identified that account for a small number of cases of familial, early-onset AD. For late onset AD (LOAD), only one susceptibility gene has so far been identified: the epsilon 4 allele of the apolipoprotein E gene. Age of onset itself has a heritability of around 50%.

Contents

  • 1 History
  • 2 Clinical features
    • 2.1 Stages and symptoms
  • 3 Diagnosis
  • 4 Pathology
    • 4.1 Biochemical characteristics
    • 4.2 Neuropathology
    • 4.3 Disease mechanism
      • 4.3.1 Genetics of AD
    • 4.4 Genetic linkage
  • 5 Epidemiology and prevention
    • 5.1 Risk reducers
    • 5.2 Risk factors
  • 6 Treatment
    • 6.1 Acetylcholinesterase inhibitors
    • 6.2 NMDA antagonists
    • 6.3 Psychosocial interventions
    • 6.4 Potential treatments
    • 6.5 Design for Alzheimer's patients
  • 7 Social issues
  • 8 Statistics on Alzheimer's Disease
  • 9 Notable cases
  • 10 See also
  • 11 References
  • 12 External links

History

Alois Alzheimer
Emil Kraepelin

In 1901, Dr. Alois Alzheimer, a German psychiatrist, interviewed a patient named Mrs. Auguste D, age 51. He showed her several objects and later asked her what she had been shown. She could not remember. He would initially record her behavior as "amnestic writing disorder," but Mrs. Auguste D. would be the first patient to be identified with Alzheimer's disease. [1]

Alzheimer would later work in the laboratory of the esteemed Emil Kraepelin in Munich, Germany. Kraepelin was the author of a leading textbook in psychiatry and was a strong believer that neuropathology could be linked to clinical psychiatric function. Early in April 1906, Auguste D died, and Alzheimer worked with two Italian physicians to examine her anatomy and neuropathology. On November 3, 1906, he presented Auguste D's case to the 37th Assembly of Southwest German Psychiatrists and described the neurofibrilary tangles and amyloid plaques that would be the hallmark of the disease. Kraepelin would later write about this case and others in his Textbook for Students and Doctors and index them under Alzheimer's disease. By 1910, the name of the disease was well established among the specialist community. [1]

For most of the twentieth century, the diagnosis of Alzheimer's disease was reserved for individuals between the ages of 45–65 who developed symptoms of presenile dementia due to the histopathologic process discovered by Dr. Alzheimer (see below for description of brain tissue changes). During this time senile dementia itself (as a set of symptoms) was considered to be a more or less normal outcome of the aging process, and thought to be due to age-related brain arterial "hardening." In the 1970s and early 1980s, because the symptoms and brain pathology were identical for Alzheimer victims older and younger than age 65, the name "Alzheimer's disease" began to be used, within and outside the medical profession, equally for afflicted individuals of all ages, although in this period the term senile dementia of the Alzheimer type (SDAT) was often used to distinguish those over 65 who did not fit the classical age criterion. Eventually, the term Alzheimer's disease was adopted formally in the psychiatric and neurological nomenclature to describe individuals of all ages with the characteristic common symptom pattern, disease course, and neuropathology. The term Alzheimer disease (without the apostrophe and s) also continues to be used commonly in the literature.

Clinical features

The usual first symptom noticed is short term memory loss which progresses from seemingly simple and often fluctuating forgetfulness (with which the disease should not be confused) to a more pervasive loss of short-term memory, then of familiar and well-known skills or objects or persons. Aphasia, disorientation and disinhibition often accompany the loss of memory. Alzheimer's disease may also include behavioral changes, such as outbursts of violence or excessive passivity in people who have no previous history of such behavior. In the later stages, deterioration of musculature and mobility, leading to bedfastness, inability to feed oneself, and incontinence, will be seen if death from some external cause (e.g. heart attack or pneumonia) does not intervene. Average duration of the disease is approximately 7–10 years, although cases are known where reaching the final stage occurs within 4–5 years, or up to 15 years.

Stages and symptoms

  • Mild — At the early stage of the disease, patients have a tendency to become less energetic or spontaneous, though changes in their behaviour often goes unnoticed even by the patients' immediate family.
  • Moderate — As the disease progresses to the middle stage, the patient might still be able to perform tasks independently, but may need assistance with more complicated activities.
  • Severe — As the disease progresses from the middle to late stage, the patient will undoubtedly not be able to perform even the simplest of tasks on their own and will need constant supervision.

Diagnosis

The diagnosis is made primarily on the basis of history, clinical observation and tests of memory and intellectual functioning over a series of weeks or months, with various physical tests (blood tests and neuroimaging) being performed to rule out alternative diagnoses. No medical tests are available to diagnose Alzheimer's disease conclusively pre-mortem. Expert clinicians who specialize in memory disorders can now diagnose AD with an accuracy of 85–90%, but a definitive diagnosis of Alzheimer's disease must await microscopic examination of brain tissue, generally at autopsy. Functional neuroimaging studies such as PET and SPECT scans can provide a supporting role where dementia is clearly present, but the type of dementia is questioned. Recent studies suggest that SPECT neuroimaging approaches clinical exam in diagnostic accuracy and may outperform exam at differentiating types of dementia (Alzheimer's disease vs. vascular dementia). [2][3] However, Alzheimer's disease remains a primarily clinical diagnosis based on the presence of characteristic neurological features and the absence of alternative diagnoses, with neuroimaging providing a supporting role where dementia is clearly present, but the type of dementia is questioned.

Interviews with family members and/or caregivers are extremely important in the initial assessment, as the sufferer him/herself may tend to minimize his symptomatology or may undergo evaluation at a time when his/her symptoms are less apparent, as quotidian fluctuations ("good days and bad days") are a fairly common feature. Such interviews also provide important information on the affected individual's functional abilities, which are a key indicator of the significance of the symptoms and the stage of dementia.

Initial suspicion of dementia may be strengthened by performing the mini mental state examination, after excluding clinical depression. Psychological testing generally focuses on memory, attention, abstract thinking, the ability to name objects, visuospatial abilities, and other cognitive functions. Results of psychological tests may not readily distinguish Alzheimer's disease from other types of dementia, but can be helpful in establishing the presence of and severity of dementia. They can also be useful in distinguishing true dementia from temporary (and more treatable) cognitive impairment due to depression or psychosis, which has sometimes been termed "pseudodementia". In addition, a 2004 study by Cervilla and colleagues showed that tests of cognitive ability provide useful predictive information up to a decade before the onset of dementia.[4] However, when diagnosing individuals with a higher level of cognitive ability, in this study those with IQ's of 120 or more, [5] patients should not be diagnosed from the standard norm but from an adjusted high-IQ norm that measured changes against the individual's higher ability level.

Pathology

Main article: Biochemistry of Alzheimer's disease

Biochemical characteristics

Alzheimer's disease has been identified as a protein misfolding disease due to the accumulation of abnormally folded amyloid beta protein in the brains of AD patients.[6] Amyloid beta, also written Aβ, is a short peptide that is an abnormal proteolytic byproduct of the transmembrane protein amyloid precursor protein (APP), whose function is unclear but thought to be involved in neuronal development.[7] The presenilins are components of proteolytic complex involved in APP processing and degradation.[8] Although amyloid beta monomers are soluble and harmless, they undergo a dramatic conformational change at sufficiently high concentration to form a beta sheet-rich tertiary structure that aggregates to form amyloid fibrils[9] that deposit outside neurons in dense formations known as senile plaques or neuritic plaques, in less dense aggregates as diffuse plaques, and sometimes in the walls of small blood vessels in the brain in a process called amyloid angiopathy or congophilic angiopathy.

AD is also considered a tauopathy due to abnormal aggregation of the tau protein, a microtubule-associated protein expressed in neurons that normally acts to stabilize microtubules in the cell cytoskeleton. Like most microtubule-associated proteins, tau is normally regulated by phosphorylation; however, in AD patients, hyperphosphorylated tau accumulated as paired helical filaments[10] that in turn aggregate into masses inside nerve cell bodies known as neurofibrillary tangles and as dystrophic neurites associated with amyloid plaques.

Neuropathology

Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in AD brains.[11] At an anatomical level, AD is characterized by gross diffuse atrophy of the brain and loss of neurons, neuronal processes and synapses in the cerebral cortex and certain subcortical regions. This results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus.[12] Levels of the neurotransmitter acetylcholine are reduced. Levels of the neurotransmitters serotonin, norepinephrine, and somatostatin are also often reduced. Glutamate levels are usually elevated.citation needed]

Disease mechanism

Three major competing hypotheses exist to explain the cause of the disease. The oldest, on which most currently available drug therapies are based, is known as the "cholinergic hypothesis" and suggests that AD begins as a deficiency in the production of the neurotransmitter acetylcholine. The medications that treat acetylcholine deficiency have served to only treat symptoms of the disease and have neither halted nor reversed it. The cholinergic hypothesis has not maintained widespread support in the face of this evidence, although cholingeric effects have been proposed to initiate large-scale aggregation[13] leading to generalized neuroinflammation.[12]

More recent hypotheses center on the effects of the misfolded and aggregated proteins, amyloid beta and tau. The two positions are lightheartedly described as "ba-ptist" and "tau-ist" viewpoints in scientific publications by Alzheimer's disease researchers. "Tau-ists" believe that the tau protein abnormalities initiate the disease cascade, while "ba-ptists" believe that beta amyloid deposits are the causative factor in the disease.[14] The tau hypothesis is supported by the long-standing observation that deposition of amyloid plaques do not correlate well with neuron loss[15]; however, a majority of researchers support the alternative hypothesis that amyloid is the primary causative agent.[14]

The amyloid hypothesis is initially compelling because the gene for the amyloid beta precursor APP is located on chromosome 21, and patients with trisomy 21 - better known as Down syndrome - who thus have an extra gene copy almost universally exhibit AD-like disorders by 40 years of age.[16][17] The traditional formulation of the amyloid hypothesis points to the cytotoxicity of mature aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cell's calcium ion homeostasis and thus inducing apoptosis.[18] A more recent and widely supported hypothesis suggests that the cytotoxic species is an intermediate misfolded form of amyloid beta, neither a soluble monomer nor a mature aggregated polymer but an oligomeric species.[19] Relevantly, much early development work on lead compounds has focused on the inhibition of fibrillization[20][21][22], but the toxic-oligomer theory would imply that prevention of oligomeric assembly is the more important process[23] or that a better target lies upstream, for example in the inhibition of APP processing to amyloid beta.[24]

Genetics of AD

Rare cases are caused by dominant genes that run in families. These cases often have an early age of onset. Mutations in presenilin-1 or presenilin-2 genes have been documented in some families. Mutations of presenilin 1 (PS1) lead to the most aggressive form of familial AD (FAD). Evidence from rodent studies suggests that the FAD mutation of PS1 results in impaired hippocampal-dependent learning which is correlated with reduced adult neurogenesis in the dentate gyrus.[25] Mutations in the APP gene on chromosome 21 can also cause early onset disease. The presenilins have been identified as essential components of the proteolytic processing machinery that produces beta amyloid peptides through cleavage of APP.

Unfortunately, the most obviously genetic cases are also the rarest. Most cases identified are "sporadic" with no clear family history. It is probable that environmental factors have to interact with a genetic susceptibility to cause development of disease. Head injury has been consistently shown to be linked to later development of AD in epidemiological studies. In addition, small cranial diameter has been shown to correlate well with early onset of recognizable symptoms. Inheritance of the epsilon 4 allele of the ApoE gene is regarded as a risk factor for development of disease, but large-scale genetic association studies raise the possibility that even this does not indicate susceptibility so much as how early one is likely to develop Alzheimer's. There is speculation among genetic experts that there are other risk and protective factor genes that may influence the development of late onset Alzheimer's disease (LOAD). Intriguing work is currently going on investigating the possibility that the regulatory regions of various Alzheimer's associated genes could be important in sporadic Alzheimer's, especially inflammatory activation of these genes. These hypotheses include the amyloid beta precursor protein [26], the beta secretase enzymes [27], insulin-degrading enzyme [28], endothelin-converting enzymes [29], and inflammatory 5-lipoxygenase gene [30].

Genetic linkage

Alzheimer's disease is definitely linked to the 1st, 14th, and 21st chromosomes, but other linkages are controversial and not, as yet, confirmed. While some genes predisposing to AD have been identified , such as ApoE4 on chromosome 19, sporadic AD also involves other risk and protective genes still awaiting confirmation.

Epidemiology and prevention

Alzheimer's disease is the most frequent type of dementia in the elderly and affects almost half of all patients with dementia. Correspondingly, advancing age is the primary risk factor for Alzheimer's. Among people aged 65, 2-3% show signs of the disease, while 25 - 50% of people aged 85 have symptoms of Alzheimer's and an even greater number have some of the pathological hallmarks of the disease without the characteristic symptoms. Every five years after the age of 65, the probability of having the disease doubles. [31] The share of Alzheimer's patients over the age of 85 is the fastest growing segment of the Alzheimer's diease population in the US, although current estimates suggest the 75-84 population has about the same number of patients as the over 85 population.[32]

The evidence relating certain behaviors, dietary intakes, environmental exposures, and diseases to the likelihood of developing Alzhemier's varies in quality and its acceptance by the medical community. It is important to understand that interventions that reduce the risk of developing disease in the first place may not alter disease progression after symptoms become apparent. Due to their observational design, studies examining disease risk factors are often at risk from confounding variables. Several recent large, randomized controlled trials—in particular the Women's Health Initiative—have called into question preventive mesasures based on cross-sectional studies. Some proposed preventive measures are even based on studies conducted solely in animals.

Risk reducers

  • Intellectual stimulation (e.g., playing chess or doing the crossword) [33]
  • Regular physical exercise [34]
  • Regular social interaction
  • A generally healthy diet low in saturated fat, supplemented in particular with:
    • B vitamins
    • Omega-3 fatty acids, especially DHA [35][36]
    • Fruit and vegetable juice [37][38]
    • High doses of the antioxidant Vitamin E (in combination with vitamin C) seem to reduce Alzheimer's risk in cross sectional studies but not in a randomized trial and so are not currently a recommended preventive measure because of observed increases in overall mortality [39] [40]
  • Cholesterol-lowering drugs (statins) reduce Alzheimer's risk in observational studies but so far not in randomized controlled trials
  • Hormone replacement therapy is no longer thought to prevent dementia based on data from the Women's Health Initiative
  • Regular use of non-steroidal anti-inflammatory drugs like ibuprofen and aspirin reduces the chance of dementia but the risks appear to outweigh the drugs' benefit as a method of primary prevention

Risk factors

  • Advancing age
  • ApoE epsilon 4 genotype (in some populations)
  • Head injury
  • Poor cardiovascular health (including smoking, diabetes, hypertension, high cholesterol)
  • Exposure to heavy metals, including aluminum and copper, is a proposed but not widely-accepted risk factor[41][42]

Treatment

There is currently no cure for Alzheimer's disease. Currently available medications offer relatively small symptomatic benefit for some patients but do not slow disease progression. The American Association for Geriatric Psychiatry published a consensus statement on Alzheimer's treatment in 2006.[43]

Acetylcholinesterase inhibitors

Acetylcholinesterase (AChE) inhibition was thought to be important because there is a reduction in activity of the cholinergic neurons. AChE-inhibitors reduce the rate at which acetylcholine (ACh) is broken down and hence increase the concentration of ACh in the brain (combatting the loss of ACh caused by the death of the cholinergin neurons). Acetylcholinesterase-inhibitors seemed to modestly moderate symptoms but do not prevent disease progression including cell death.

Examples include:

  • tacrine - no longer clinically used
  • donepezil - (marketed as Aricept)
  • galantamine - (marketed as Razadyne in the U.S.A. Marketed as Reminyl or Nivalin in the rest of the world)
  • rivastigmine - (marketed as Exelon)

There is significant doubt as to the effectiveness of cholinesterase inhibitors. A number of recent articles have criticized the design of studies reporting benefit from these drugs, concluding that they have doubtful clinical utility, are costly, and confer many side effects.[44] [45] The pharmaceutical companies, but also some independent clinicians, dispute the conclusions of these articles. A transdermal patch is under development that may ease administration of rivastigmine.[46]

NMDA antagonists

Recent evidence of the involvement of glutamatergic neuronal excitotoxicity in the aetiology of Alzheimer's disease led to the development and introduction of memantine. Memantine is a novel NMDA receptor antagonist, and has been shown to be moderately clinically efficacious. [47]

Psychosocial interventions

Cognitive and behavioral interventions and rehabilitation strategies may be used as an adjunct to pharmacologic treatment, especially in the early to moderately advanced stages of disease. Treatment modalities include counseling, psychotherapy (if cognitive functioning is adequate), reminiscent therapy, reality orientation therapy, and behavioral reinforcements as well as cognitive rehabilitation training.[48][49]

Potential treatments

A large number of potential treatments for Alzheimer's disease are currently under investigation, including four compounds being studied in phase 3 clinical trials. Xaliproden had been shown to reduce neurodegeneration in animal studies. [50] Tramiprosate (3APS or Alzhemed) is a GAG-mimetic molecule that is believed to act by binding to soluble amyloid beta to prevent the accumulation of the toxic plaques. R-flurbiprofen (MPC-7869) is a gamma secretase modulator sometimes called a selective amyloid beta 42 lowering agent. It is believed to reduce the production of the toxic amyloid beta in favor of shorter forms of the peptide. [51] [52] Leuprolide is also being studied for Alzheimer’s. It is hypothesized to work by reducing leutenizing hormone levels which may be causing damage in the brain as one ages. [53]

  • Vaccines for Alzheimer's, unlike typical vaccines, would be used to treat diagnosed patients rather than for disease prevention. Ongoing efforts are based on the idea that, by training the immune system to recognize and attack beta-amyloid, the immune system might reverse deposition of amyloid and thus stop the disease. Initial results using this approach in animals were promising. However, when the first vaccines were used in humans, a small fraction of participants (6%, 18 of 300) developed encephalitis and the trials were stopped. Participants in the halted trials continued to be followed, and some showed possible benefit in the form of slower progression of the disease. [54] Work is continuing on less toxic Aβ vaccines, such as a DNA-based therapy that recently showed promise in mice.
  • Proposed alternative treatments for Alzheimer's include a range of herbal compounds and dietary supplements. In general, research on the efficacy of these substances is either non-existent or far too weak to support therapeutic claims of improved memory or slowed disease progression.

In a 2006 review[43], Vitamin E in doses below 400 IU was mentioned as having conflicting evidence in efficacy to prevent AD. Higher doses were discouraged as these may be linked with higher mortality. Ginkgo biloba did not show enough long-term efficacy to recommend its use, but it is being studied in a large randomized clinical study in the US. [55] [56]

Laboratory studies with cells and animals continually fuel the pipeline of potential treatments. Some currently approved drugs such as statins and thiazolidinediones [57] have also been under investigation for the treatment and prevention of Alzheimer’s. Recent clinical trials for Phase 2 and Phase 3 in this category have taken 12 to 18 months under study drug, plus addtional months for patient enrollment and analysis. Compounds that are just entering into human trials or are in pre-clinical trials would be at least 4 years from being available to the public and would be available only if they can demonstrate safety and efficacy in human trials.

Recent study shows that tetrahydrocannabinol (the active ingredient in cannabis) may inhibit the formation of amyloid plaque, the primary pathological marker for Alzheimer's disease. In fact, the Scripps Research Institute study says that THC is "a considerably superior inhibitor of [amyloid plaque] aggregation" to several currently approved drugs for treating the disease. Further research is needed but the results are conclusive enough to warrant further investigation. [58]

Design for Alzheimer's patients

  • According to a small Boston University study, boldly colored tableware aids those with severe AD, helping people overcome a diminished sensitivity to visual contrast, a condition often found among people with advanced AD. Study participants were found to increase by 25% or more the amount they ate and drank.[59]

Social issues

Alzheimer's is considered to be a major public health challenge since the median age of the industrialized world's population is increasing gradually. Indeed, much of the concern about the solvency of governmental social safety nets is founded on estimates of the costs of caring for baby boomers, assuming that they develop Alzheimer's in the same proportions as earlier generations. For this reason, money spent informing the public of available effective prevention methods may yield disproportionate benefits.

The role of family caregivers has also become more prominent, as care in the familiar surroundings of home may delay onset of some symptoms and delay or eliminate the need for more professional and costly levels of care. However, home-based care may entail tremendous economic, emotional, and even psychological costs as well. Family caregivers often give up time from work and foregoing pay to spend 47 hours per week on average with an affected loved one who frequently cannot be left alone. Direct and indirect costs of caring for an Alzheimer's patient average $77,500 per year. [60]

Statistics on Alzheimer's Disease

  • AD was the 7th leading cause of death in 2004, with 65,829 number of deaths (and rising). [61]
  • At over $100 billion per year, AD is the third most costly disease in the U.S., after heart disease and cancer [62]
  • There are an estimated 24 million people with dementia worldwide.[63]
  • By 2040, it is projected that this figure will have increased to 81 million.
  • An estimated 4.5 million Americans have Alzheimer’s disease.[64]
  • It is projected that 14.3 million Americans will have the disease by mid-century-a 350 percent increase from 2000.[65]
  • The federal government estimates spending approximately $647 million for Alzheimer’s disease research in fiscal year 2005.[66]
  • The average lifetime cost of care for an individual with Alzheimer’s is $174,000.

Notable cases

Notable cases of Alzheimer's disease have included President Ronald Reagan, Charlton Heston, Ralph Waldo Emerson, and Rita Hayworth. For a more comprehensive list, see List of famous Alzheimer's disease sufferers.

See also

  • Other major neurodegenerative diseases including Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis
  • Diseases included in the differential diagnosis of Alzheimer's, including dementia with Lewy bodies, frontotemporal dementia, familial Alzheimer disease, and multi-infarct dementia
  • Information on the molecular pathogenesis of Alzheimer's disease, including amyloid beta, beta-secretase, and tau protein
  • Articles related to memory, including memory and aging, dementia, and amnesia
  • Article concerning a new approach for elucidating the structure-function relationships of important metallochaperone proteins relevant to diagnosis and therapy of protein-misfolding diseases.

References

  1. ^ a b Maurer K, Maurer U (2003). Alzheimer The life of a physician and career of a disease. New York: Columbia University Press. ISBN 0231118961.
  2. ^ Dougall N, Bruggink S, Ebmeier K. "Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia.". Am J Geriatr Psychiatry 12 (6): 554-70. PMID 15545324.
  3. ^ Bonte F, Harris T, Hynan L, Bigio E, White C (2006). "Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation.". Clin Nucl Med 31 (7): 376-8. PMID 16785801.
  4. ^ Cervilla et al (2004). Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype. Psychiatry 2004;75:1100-1106.. Retrieved on August 6, 2006.
  5. ^ Dorene Rentz, Brigham and Women's Hospital's Department of Neurology and Harvard Medical School. More Sensitive Test Norms Better Predict Who Might Develop Alzheimer's Disease. Neuropsychology, published by the American Psychological Association. Retrieved on August 6, 2006.
  6. ^ Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.". Neuromolecular Med 4 (1-2): 21-36. PMID 14528050.
  7. ^ Kerr M, Small D (2005). "Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development.". J Neurosci Res 80 (2): 151-9. PMID 15672415.
  8. ^ Cai D, Netzer W, Zhong M, Lin Y, Du G, Frohman M, Foster D, Sisodia S, Xu H, Gorelick F, Greengard P (2006). "Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation.". Proc Natl Acad Sci U S A 103 (6): 1941-6. PMID 16449386.
  9. ^ Ohnishi S, Takano K (2004). "Amyloid fibrils from the viewpoint of protein folding.". Cell Mol Life Sci 61 (5): 511-24. PMID 15004691.
  10. ^ Goedert M, Klug A, Crowther R (2006). "Tau protein, the paired helical filament and Alzheimer's disease.". J Alzheimers Dis 9 (3 Suppl): 195-207. PMID 16914859.
  11. ^ Tiraboschi P, Hansen L, Thal L, Corey-Bloom J (2004). "The importance of neuritic plaques and tangles to the development and evolution of AD.". Neurology 62 (11): 1984-9. PMID 15184601.
  12. ^ a b Wenk G. "Neuropathologic changes in Alzheimer's disease.". J Clin Psychiatry 64 Suppl 9: 7-10. PMID 12934968.
  13. ^ Shen Z (2004). "Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease.". Med Hypotheses 63 (2): 308-21. PMID 15236795.
  14. ^ a b Mudher A, Lovestone S (2002). "Alzheimer's disease-do tauists and baptists finally shake hands?". Trends Neurosci 25 (1): 22-6. PMID 11801334.
  15. ^ Schmitz C, Rutten B, Pielen A, Schäfer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch H, Pradier L, Bayer T (2004). "Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease.". Am J Pathol 164 (4): 1495-502. PMID 15039236.
  16. ^ Nistor M, Don M, Parekh M, Sarsoza F, Goodus M, Lopez GE, Kawas C, Leverenz J, Doran E, Lott IT, Hill M, Head E (2006). "Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.". Neurobiol Aging (epub). PMID 16904243.
  17. ^ Lott I, Head E (2005). "Alzheimer disease and Down syndrome: factors in pathogenesis.". Neurobiol Aging 26 (3): 383-9. PMID 15639317.
  18. ^ Yankner B, Duffy L, Kirschner D (1990). "Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.". Science 250 (4978): 279-82. PMID 2218531.
  19. ^ Blanchard BJ, Hiniker AE, Lu CC, Margolin Y, Yu AS, Ingram VM (2000). "Elimination of Amyloid beta Neurotoxicity.". J Alzheimers Dis 2 (2): 137-149. PMID 12214104.
  20. ^ Blanchard B, Chen A, Rozeboom L, Stafford K, Weigele P, Ingram V (2004). "Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule.". Proc Natl Acad Sci U S A 101 (40): 14326-32. PMID 15388848.
  21. ^ Porat Y, Abramowitz A, Gazit E (2006). "Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism.". Chem Biol Drug Des 67 (1): 27-37. PMID 16492146.
  22. ^ Kanapathipillai M, Lentzen G, Sierks M, Park C (2005). "Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid.". FEBS Lett 579 (21): 4775-80. PMID 16098972.
  23. ^ Lee K, Shin B, Shin K, Kim D, Yu J (2005). "A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42).". Biochem Biophys Res Commun 328 (4): 816-23. PMID 15707952.
  24. ^ Espeseth A, Xu M, Huang Q, Coburn C, Jones K, Ferrer M, Zuck P, Strulovici B, Price E, Wu G, Wolfe A, Lineberger J, Sardana M, Tugusheva K, Pietrak B, Crouthamel M, Lai M, Dodson E, Bazzo R, Shi X, Simon A, Li Y, Hazuda D (2005). "Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics.". J Biol Chem 280 (18): 17792-7. PMID 15737955.
  25. ^ Wang R, Dineley K, Sweatt J, Zheng H (2004). "Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis.". Neuroscience 126 (2): 305-12. PMID 15207348.
  26. ^ Lahiri D, Ghosh C, Ge Y. "A proximal gene promoter region for the beta-amyloid precursor protein provides a link between development, apoptosis, and Alzheimer's disease.". Ann N Y Acad Sci 1010: 643-7. PMID 15033805.
  27. ^ Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M. "Molecular genetics of Alzheimer's disease and aging.". Methods Find Exp Clin Pharmacol 27 Suppl A: 1-573. PMID 16470248.
  28. ^ Nowotny P, Hinrichs A, Smemo S, Kauwe J, Maxwell T, Holmans P, Hamshere M, Turic D, Jehu L, Hollingworth P, Moore P, Bryden L, Myers A, Doil L, Tacey K, Gibson A, McKeith I, Perry R, Morris C, Thal L, Morris J, O'Donovan M, Lovestone S, Grupe A, Hardy J, Owen M, Williams J, Goate A (2005). "Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme.". Am J Med Genet B Neuropsychiatr Genet 136 (1): 62-8. PMID 15858813.
  29. ^ Funalot B, Ouimet T, Claperon A, Fallet C, Delacourte A, Epelbaum J, Subkowski T, Léonard N, Codron V, David J, Amouyel P, Schwartz J, Helbecque N (2004). "Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease.". Mol Psychiatry 9 (12): 1122-8, 1059. PMID 15340356.
  30. ^ Manev H, Manev R (2006). "5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease.". Med Hypotheses 66 (3): 501-3. PMID 16278051.
  31. ^ Gorelick P (2004). "Risk factors for vascular dementia and Alzheimer disease.". Stroke 35 (11 Suppl 1): 2620-2. PMID 15375299.
  32. ^ Hebert L, Scherr P, Bienias J, Bennett D, Evans D (2003). "Alzheimer disease in the US population: prevalence estimates using the 2000 census.". Arch Neurol 60 (8): 1119-22. PMID 12925369.
  33. ^ Verghese J, Lipton R, Katz M, Hall C, Derby C, Kuslansky G, Ambrose A, Sliwinski M, Buschke H (2003). "Leisure activities and the risk of dementia in the elderly.". N Engl J Med 348 (25): 2508-16. PMID 12815136.
  34. ^ Larson E, Wang L, Bowen J, McCormick W, Teri L, Crane P, Kukull W (2006). "Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older.". Ann Intern Med 144 (2): 73-81. PMID 16418406.
  35. ^ Lim W, Gammack J, Van Niekerk J, Dangour A. "Omega 3 fatty acid for the prevention of dementia.". Cochrane Database Syst Rev: CD005379. PMID 16437528.
  36. ^ Morris M, Evans D, Tangney C, Bienias J, Wilson R (2005). "Fish consumption and cognitive decline with age in a large community study.". Arch Neurol 62 (12): 1849-53. PMID 16216930.
  37. ^ Dai Q, Borenstein A, Wu Y, Jackson J, Larson E (2006). "Fruit and vegetable juices and Alzheimer's disease: the Kame Project.". Am J Med 119 (9): 751-9. PMID 16945610.
  38. ^ Joseph J, Fisher D, Carey A (2004). "Fruit extracts antagonize Abeta- or DA-induced deficits in Ca2+ flux in M1-transfected COS-7 cells.". J Alzheimers Dis 6 (4): 403-11; discussion 443-9. PMID 15345811.
  39. ^ Petersen R, Thomas R, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck C, Thal L (2005). "Vitamin E and donepezil for the treatment of mild cognitive impairment.". N Engl J Med 352 (23): 2379-88. PMID 15829527.
  40. ^ Zandi P, Anthony J, Khachaturian A, Stone S, Gustafson D, Tschanz J, Norton M, Welsh-Bohmer K, Breitner J (2004). "Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study.". Arch Neurol 61 (1): 82-8. PMID 14732624.
  41. ^ Alzheimer's Disease and Aluminum - NIEHS Alphabetical Listing of Health Topics. Retrieved on 9/20/2006.
  42. ^ Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, Moffa F, Caridi I, Cassetta E, Pasqualetti P, Calabrese L, Lupoi D, Rossini P (2006). "Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau.". Neurology 67 (1): 76-82. PMID 16832081.
  43. ^ a b Lyketsos C, Colenda C, Beck C, Blank K, Doraiswamy M, Kalunian D, Yaffe K (2006). "Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.". Am J Geriatr Psychiatry 14 (7): 561-72. PMID 16816009. [1]
  44. ^ Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004). "Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.". Lancet 363 (9427): 2105-15. PMID 15220031.
  45. ^ Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H, van den Bussche H (2005). "Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.". BMJ 331 (7512): 321-7. PMID 16081444.
  46. ^ Exelon Patch, The First Transdermal Therapy For Alzheimer's Disease, May Provide Promising New Approach To Treatment Of Dementia
  47. ^ Areosa Sastre A, McShane R, Sherriff F. "Memantine for dementia.". Cochrane Database Syst Rev: CD003154. PMID 15495043.
  48. ^ Olazarán J, Muñiz R, Reisberg B, Peña-Casanova J, del Ser T, Cruz-Jentoft A, Serrano P, Navarro E, García de la Rocha M, Frank A, Galiano M, Fernández-Bullido Y, Serra J, González-Salvador M, Sevilla C (2004). "Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.". Neurology 63 (12): 2348-53. PMID 15623698.
  49. ^ Clare L, Woods R, Moniz Cook E, Orrell M, Spector A. "Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia.". Cochrane Database Syst Rev: CD003260. PMID 14583963.
  50. ^ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). "Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats.". Invest Radiol 37 (6): 321-7. PMID 12021588.
  51. ^ Zamrini E (2006). "Emerging Drug Therapies for Dementia.". Geriatrics Aging 9 (2): 107,110-113. [2]
  52. ^ Eriksen J, Sagi S, Smith T, Weggen S, Das P, McLendon D, Ozols V, Jessing K, Zavitz K, Koo E, Golde T (2003). "NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.". J Clin Invest 112 (3): 440-9. PMID 12897211.
  53. ^ Casadesus G, Garrett M, Webber K, Hartzler A, Atwood C, Perry G, Bowen R, Smith M (2006). "The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease.". Drugs R D 7 (3): 187-93. PMID 16752944.
  54. ^ Alzheimer’s Association Fact Sheet: AN1792. Retrieved on 9/20/2006.
  55. ^ Birks J, Grimley E, Van Dongen M. "Ginkgo biloba for cognitive impairment and dementia.". Cochrane Database Syst Rev: CD003120. PMID 12519586.
  56. ^ DeKosky S, Fitzpatrick A, Ives D, Saxton J, Williamson J, Lopez O, Burke G, Fried L, Kuller L, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C (2006). "The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia.". Contemp Clin Trials 27 (3): 238-53. PMID 16627007.
  57. ^ Landreth G (2006). "PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.". Exp Neurol 199 (2): 245-8. PMID 16733054.
  58. ^ Marijuana's Active Ingredient Shown to Inhibit Primary Marker of Alzheimer's Disease
  59. ^ [http://www.bu.edu/phpbin/news/releases/display.php?id=778 BRIGHTLY COLORED CUPS, PLATES SPUR FOOD, BEVERAGE CONSUMPTION IN ADVANCED ALZHEIMER'S DISEASE Boston University psychologists study contrast sensitivity deficiency in AD patients]
  60. ^ "The MetLife Study of Alzheimer’s Disease: The Caregiving Experience". MetLife Mature Market Institute ® (August 2006). [3]
  61. ^ [4], National Vital Statistics Report.
  62. ^ [5] Alzheimer's Drug Discovery Foundation 2005 Annual Report
  63. ^ [6], Alzheimer's Disease International.
  64. ^ [7], Alzheimer's Association
  65. ^ [8]Diagnostic Center for Alzheimer’s Disease
  66. ^ [9], Alzheimer's Association.

External links

Wikimedia Commons has media related to:
Alzheimer's disease
  • Alzheimer's Association - The major Alzheimer's support and advocacy group in the United States provides excellent information on topics ranging from basics of diagnosis and caregiving to the disease's legal implications and ways to talk to children about the disease. Similar groups provide country-specific information in Australia and Canada.
  • Alzheimer's Research Forum - A website intended to provide information to and foster collaboration among scientists and physicians conducting research on Alzheimer's. Features debates between and article annotations by many top Alzheimer's researchers
  • National Institute on Aging - Substantial website by a division of the U.S. National Institutes of Health with links to information about ongoing clinical studies
  • Alzheimer's Disease Research Centers - Links to each of the NIH-funded centers of excellence for Alzheimer's disease located at academic medical centers scattered throughout the U.S.
  • OMIM - Running, highly technical synopsis of research on Alzheimer's disease maintained by the NIH
  • Journal of Alzheimer's Disease - Subscription required for full text
  • eMedicine - Well-organized article on Alzheimer's
Search Term: "Alzheimer%27s_disease"
alzheimers news and alzheimers articles

Here's our top rated alzheimers links for the day:

Sunrise of Leominster 978-537-7600 Assisted Living, Alzheimers Care 6Beth Avenue 

Landmark - Nov 16 1:50 AM
Sunrise of Leominster 978-537-7600 Assisted Living, Alzheimer’s Care 6Beth Avenue at Route 12, Leominster, MA 01453 For information and a FREE online newsletter, visit www.sunriseseniorliving.com Sunrise of Leominster… Established, elegant senior living Specializing in Assisted Living and Alzheimer’s Care At Sunrise, we celebrate each of our resi-dents for the unique individual they are.

'Lifesaver' Helps Locate Lost Alzheimers Patients 
WFRV-TV Green Bay - Nov 12 8:47 PM
A new program in Brown County called Operation Lifesaver is helping to locate Alzheimers patients who may be lost by simply wearing a bracelet.

Upcoming local events to focus on dealing with Alzheimers disease 
Wausau Daily Herald - Nov 13 2:44 AM
Alzheimers disease is a slow, debilitating illness that not only causes the victim to die, but places a great toll on the families and caregivers.

Thank you for viewing the alzheimers page alzheimers. 

alzheimer
alzhiemers
alzhimers
alzeimers
alsheimers
alheimers
azheimers
alzhemers
alzhemiers
alzheimrs
alzheiners
alzheiers
alhzeimers
alzehimers

 

 Ever wondered what others are searching for in relation to alzheimers? Now you can see.  Below is a listing of  what everyone else is searching for in regard to alzheimers.

1. alzheimers
2. alzheimer
3. alzheimers disease
4. alzheimer disease
5. alzheimers association
6. alzheimers disease history
7. ontario alzheimer care
8. toronto alzheimer care
9. alzheimers symptoms
10. alzheimer spa
11. alzheimers association central
12. alzheimers disease on european servers
13. alzheimers facilities
14. alzheimer de gntique d'exp
15. labeled alzheimers images
16. tracking device for alzheimer patients
17. international conference on alzheimers disease
18. alzheimer research
19. alzheimers cost disease
20. alzheimer disease european servers
21. alzheimers disease and aluminum
22. down syndrome and alzheimers disease
23. end stage alzheimers
24. symptoms of alzheimers
25. alzheimer books
26. alzheimer disease and aluminum
27. alzheimers care training program videos
28. alzheimers disease poem
29. alzheimer and flu shot
30. alzheimer disease history
31. alzheimer disease stages
32. alzheimers treatment
33. information on alzheimers disease
34. stages of alzheimers
35. alzheimers brain
36. aluminum alzheimers disease
37. alzheimer memoria demencias
38. alzheimers residential care los angeles
39. cause and symptom of alzheimers disease
40. alzheimer research articles
41. alzheimers diesease info
42. sign of alzheimers disease
43. alzheimers disease prognosis
44. alzheimers screening test
45. alzheimer association
46. alzheimer testing
47. alzheimers disease assessment scale
48. alzheimers disease statistics
49. alzheimers patient evaluation
50. alzheimers residential care facility los angeles
51. brain with alzheimers s disease
52. alzheimer tbi traumatic brain injury
53. alzheimers disease research
54. alzheimers flu shot
55. alzheimers medications
56. alzheimers pictures
57. alzheimers prevention
58. alzheimers research
59. alois alzheimer
60. alzheimer news
61. alzheimer textbooks
62. alzheimers book disease
63. alzheimers disease association
64. alzheimers disease treatment
65. early sign of alzheimers disease
66. flu shot and alzheimers
67. lap quilt alzheimer patients
68. alzheimers and down syndrome
69. alzheimers conference disease international
70. alzheimers disease and support group
71. alzheimers test
72. early signs of alzheimers
73. home care versus nursing home for alzheimers
74. alzheimer drugs
75. alzheimers clinical trials
76. alzheimers disease diagnosis
77. alzheimers disease essay
78. alzheimers s disease
79. alzheimers tests
80. early onset alzheimers disease
81. early stage alzheimers disease
82. alzheimer symptoms
83. alzheimers definition disease
84. alzheimers disease disorder related
85. alzheimers disease information
86. alzheimers disease sign and symptom
87. alzheimers parkinsons disease male
88. cause of alzheimers disease
89. lipitor alzheimers
90. pet scan alzheimers disease
91. activities for alzheimers patients
92. alzheimer products
93. alzheimers + powerlessness
94. alzheimers disease and caregiver
95. alzheimers disease the final stage
96. alzheimers journal an 1792 new england journal of
97. alzheimers residential treatment home tampa florida
98. alzheimers security device
99. anxiety and depression in people with alzheimers
100. fact about alzheimers disease
101. famous people with alzheimers disease
102. information on alzheimers
103. international conference on alzheimers
104. symptoms of alzheimers disease
105. testing for alzheimers disease
106. treatment for alzheimers disease
107. activities to do with alzheimers patients
108. alos alzheimer
109. alzheimer care
110. alzheimers anemic
111. alzheimers care carolina columbia south
112. alzheimers care community
113. alzheimers diet plans
114. alzheimers disease drug
115. alzheimers disease education
116. alzheimers disease end stage
117. alzheimers disease help
118. alzheimers disease international
119. alzheimers disease nutrition
120. alzheimers disease research center
121. alzheimers disease search
122. alzheimers support
123. brain cat scans of alzheimers patients
124. dementia alzheimers disease
125. diagnosing alzheimers disease
126. emotion processing in alzheimers disease
127. familial alzheimers disease
128. late stage alzheimers disease
129. symptom of alzheimers disease
130. symptoms of alzheimer
131. alzheimer and nutrition
132. alzheimer diagnosis
133. alzheimer s international conference
134. alzheimers disease parkinsons
135. alzheimers disease pathophysiology
136. alzheimers disease picture
137. alzheimers disease prevent
138. alzheimers disease society
139. alzheimers disease stage
140. alzheimers disease type
141. alzheimers down syndrome
142. alzheimers foundation
143. alzheimers medication
144. alzheimers s disease picture
145. early symptoms of alzheimers
146. prevalence of alzheimer in people with down syndrome
147. what is alzheimers
148. 2527s alzheimers disease
149. abstract on alzheimers disease
150. alpha lipoic acid alzheimers disease
151. aluminum and alzheimers
152. alzheimer dementia
153. alzheimer lap quilt fidget
154. alzheimers disease and associated disorder
155. alzheimers disease and curry
156. alzheimers drugs
157. alzheimers id
158. alzheimers news
159. article on alzheimers disease
160. dementia alzheimers support groups connecticut
161. diagnosing alzheimers
162. forest hills alzheimers
163. progression of alzheimers disease
164. stem cell research alzheimers disease
165. 9th alzheimers conference disease international
166. alzheimer patient care videos
167. alzheimer stages
168. alzheimer trainer
169. alzheimers and the flu shot
170. alzheimers association disease disorder related
171. alzheimers care day
172. alzheimers care home in nursing patient
173. alzheimers care nursing
174. alzheimers center disease education referral
175. alzheimers conference disease disorder international related
176. alzheimers dementia
177. alzheimers disease and flu shots
178. alzheimers disease support
179. alzheimers drug treatment
180. alzheimers support + sarnia
181. alzheimers support group toms river
182. alzheimers vitamin b12 sublingual
183. bible study alzheimer
184. communicating with alzheimers patients
185. early alzheimers
186. etiolog?a del alzheimer
187. final stages of alzheimers
188. how long do stages of alzheimers last
189. new england journal of medicine and alzheimers
190. alabama alzheimers disease
191. alzheimer cognitive therapy effective
192. alzheimers + memory care interventions
193. alzheimers breaking news
194. alzheimers care nursing plan
195. alzheimers disease clinical trials
196. alzheimers disease fact
197. alzheimers disease nutritional supplement
198. alzheimers journal an 1792 new england journal of medicine
199. alzheimers stage
200. effects of alzheimers disease
201. federal income tax filing status alzheimers
202. genetic testing alzheimer disease
203. is there any help for alzheimers victim
204. marijuana alzheimers
205. popular news on alzheimers disease release today find
206. raising alzheimers awareness
207. ronald reagan alzheimers disease
208. symptoms alzheimers
209. activities for alzheimers
210. advances in the medical field against alzheimers
211. alzheimer care facilities
212. alzheimers 27s disease
213. alzheimers and vitamin b12 and sublingual
214. alzheimers caregiver
215. alzheimers caregiver support
216. alzheimers disease and prevention
217. alzheimers disease flu shots
218. alzheimers disease journal on
219. alzheimers foundations in florida
220. alzheimers memory walk
221. alzheimers patient security
222. alzheimers support groups
223. alzheimers support groups in tucson az
224. arden courts alzheimers assisted living
225. cognitive therapy alzheimer
226. dementia and or alzheimers and spirituality
227. early onset alzheimers
228. early symptom of alzheimers disease
229. flu shots and alzheimers
230. genetic testing for alzheimers
231. history of alzheimers
232. hormone replacement therapy and alzheimers disease
233. is alzheimers hereditory
234. meds for alzheimers patients
235. nursing home alzheimer care
236. prevent of alzheimer
237. short term memory in alzheimers
238. symptons of alzheimers
239. alzheimer dementie
240. alzheimer fotos o ilustraciones
241. alzheimer genome
242. alzheimer quilts
243. alzheimer tests
244. alzheimer tracking system
245. alzheimers and wandering
246. alzheimers association washington
247. alzheimers ativan
248. alzheimers awarness bracelets
249. alzheimers diagnosis
250. alzheimers disease and mediacation
251. alzheimers disease down syndrome
252. alzheimers disease medication
253. alzheimers drugs patch
254. alzheimers early symptoms
255. alzheimers patients
256. alzheimers progression
257. alzheimers support group message board
258. apolipoprotein e3 atherosclerosis alzheimers
259. cause of alzheimer
260. causes of alzheimers
261. death from alzheimers
262. drug that reverses alzheimers
263. familial alzheimers
264. folic acid alzheimers
265. head injury alzheimers
266. info on alzheimers
267. maureen mcnulty alzheimer
268. mental health alzheimer vs dimentia
269. more on vitamins and alzheimers disease health news
270. natural healing for alzheimers disease
271. prevalence of alzheimers disease
272. prevention of alzheimers disease
273. self-test for alzheimers
274. signs of alzheimers
275. stage of alzheimers
276. therapy for alzheimers disease
277. vitamin b12 treatment in alzheimers
278. 39 alzheimers disease s
279. advanced alzheimers and seizures
280. alois alzheimers
281. aluminum alzheimers
282. alzheimer animation flash
283. alzheimer care niagara falls ontario
284. alzheimer diet plans
285. alzheimer drug patch
286. alzheimer drug treatment
287. alzheimer foundation
288. alzheimer medications
289. alzheimer mutant genes
290. alzheimers assoc
291. alzheimers care
292. alzheimers disease brain
293. alzheimers disease emedicine
294. alzheimers disease mailing list
295. alzheimers disease test
296. alzheimers disease testing
297. alzheimers early onset
298. alzheimers final stages death
299. alzheimers genetic testing
300. alzheimers guardianship
301. alzheimers homes las vegas
302. alzheimers information and referral services
303. alzheimers powerpoint
304. alzheimers society
305. alzheimers support group
306. alzheimers testing
307. alzheimers vegan
308. alzheimers videos
309. alzheimers walk
310. american journal of alzheimers disease
311. cognitive rehabilitation + alzheimers
312. dementia alzheimers support groups fconnecticut
313. diet and exercise to prevent alzheimers disease
314. driving with alzheimers
315. early alzheimer diagnostic tools
316. financial help for alzheimers
317. first sign of alzheimers
318. florida home health alzheimer training program
319. how to cure alzheimer
320. in-service tapes communication with alzheimers patients
321. lipitor and alzheimers
322. maladie alzheimer
323. medications for alzheimers
324. moving alzheimers patient
325. new drugs for treatment of alzheimers disease
326. nun study + alzheimers
327. residential alzheimer s care
328. ronald reagan alzheimers
329. stage 7 alzheimers
330. what is alzheimers disease
331. 3 stages of alzheimers
332. aberdeen alzheimers support
333. adirondack rockers for alzheimers patients
334. alzheimer care louisville
335. alzheimer families
336. alzheimer national association
337. alzheimer s community care
338. alzheimer trainer online
339. alzheimer walk
340. alzheimers and brain trauma
341. alzheimers and seizures
342. alzheimers association in mobile al
343. alzheimers canada
344. alzheimers care facility
345. alzheimers care los angeles
346. alzheimers common symptom
347. alzheimers d maladie
348. alzheimers day care
349. alzheimers diease
350. alzheimers diseas
351. alzheimers disease center
352. alzheimers disease symptoms
353. alzheimers grape juice
354. alzheimers in service videos
355. alzheimers meat
356. alzheimers medicare home health care benefits
357. alzheimers perception
358. alzheimers pet scan test
359. alzheimers stages
360. alzheimers support group in dallas- fort worth texas
361. alzheimers training
362. alzheimers treatments
363. alzheimers type dementia
364. americans with alzheimers disease
365. and and disease alzheimers inflammation heart
366. books about alzheimers
367. causes of alzheimer disease
368. charlton heston alzheimers
369. chicago alzheimers home care
370. chicago caregiving for alzheimer patients
371. cognitive therapy for alzheimers patients
372. cycad seed toxins als and alzheimers
373. dept of veterans affairs search and rescue alzheimers
374. diabetes and alzheimers
375. down syndrome alzheimer s disease
376. d?mence de type alzheimer
377. early signs alzheimers
378. enfermedad de alzheimers
379. estrogen alzheimers
380. georgia alzheimers care facilities
381. high calorie diets for alzheimers patients
382. international alzheimer conference
383. international conference alzheimers
384. is alzheimers hereditory from the father or mother side
385. john douglas french center for alzheimers disease
386. juice alzheimers disease
387. late stage alzheimer symptoms
388. medical journal alzheimers
389. my mother has alzheimers
390. nonverbal communication alzheimers dementia
391. pictures of alzheimers disease
392. stages alzheimer disease
393. stem cell alzheimers
394. supplements for alzheimers
395. vitamins alzheimer disease health news
396. vitamins for alzheimers patients
397. zocor alzheimers
398. alzheimer apoptosis
399. alzheimer food
400. alzheimer genetic test anonymous
401. alzheimer id jewelry
402. alzheimer society
403. alzheimer spa?ol
404. alzheimer support groups
405. alzheimer wheelchair
406. alzheimers + brain disuse
407. alzheimers activities
408. alzheimers activity with coupons
409. alzheimers and bipolar
410. alzheimers and digital games
411. alzheimers and parkinsons disease
412. alzheimers and refuses help
413. alzheimers articles
414. alzheimers association central &north florida
415. alzheimers australia
416. alzheimers between dementia difference
417. alzheimers care facilities oklahoma
418. alzheimers caregiver assistance
419. alzheimers causes
420. alzheimers dieses
421. alzheimers disease forum
422. alzheimers disease medicine
423. alzheimers disease progression
424. alzheimers drug new treatment
425. alzheimers facilities/west palm beach/florida
426. alzheimers frank broyles
427. alzheimers history
428. alzheimers home gig harbour
429. alzheimers home las vegas
430. alzheimers information
431. alzheimers montessori activities books
432. alzheimers neurology
433. alzheimers nursing homes in hillsborough county
434. alzheimers obit stem walk
435. alzheimers organization
436. alzheimers plaques and tangles
437. alzheimers residential care in texas
438. alzheimers treat
439. alzheimers trials
440. alzheimers word tests
441. bionic gloves alzheimer
442. brain research alzheimers
443. causes of alzheimers disease
444. causes treatments of alzheimers disease
445. condition alzheimers disease state
446. deminsia and or alzheimers and spirituality
447. diabetes alzheimers
448. diagnose alzheimer
449. diagnosis of alzheimers
450. diet and alzheimers
451. difference between alzheimers and dementia
452. early onset alzheimers genetic mutation
453. effective alzheimer drugs
454. effects of smoking alcohol apoe genotype alzheimer disease
455. emory healthcare alzheimers nursing home georgia
456. end stages of alzheimers
457. eplilepsy and alzheimer
458. estrogen causes of alzheimers disease
459. felipe jacome alzheimer tucson
460. forget me knots alzheimer
461. frontal lobe alzheimers
462. gardens for people with alzheimer
463. general information on alzheimers disease
464. how to treat alzheimer
465. information about alzheimer
466. information on alois alzheimer
467. last stage of alzheimers
468. late stage alzheimers
469. mass alzheimers association
470. medicare funded alzheimer products
471. medicare home health care alzheimers
472. meneer alzheimer
473. meta-analysis and alzheimer disease
474. oklahoma alzheimers association
475. over the counter medication for alzheimer disese
476. pace at which alzheimers patients decline
477. pet scan alzheimers
478. piracetam and alzheimer
479. question guardianship man 93 alzheimers dementia incompetent
480. rapid-onset alzheimers
481. sensory + tactile stimulation products + alzheimers
482. signs of alzheimers disease
483. spiritual needs in alzheimers
484. stages of alzheimers last how long
485. sympathy alzheimers
486. symptom alzheimers
487. the future of alzheimers
488. vitamin e alzheimers
489. vitamin e and alzheimers
490. warning signs of alzheimers disease
491. ziekte van alzheimer
492. activites memory alzheimers
493. activities for alzheimer patients
494. activities for people with alzheimers
495. allegra alzheimers
496. alternative medicine for alzheimers disease
497. aluminum alzheimer
498. alzheimer aids
499. alzheimer asociaciones espa?a
500. alzheimer association writing